Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Common Equity (2016 - 2025)

Catalyst Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $954.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 31.15% year-over-year to $954.3 million; the TTM value through Dec 2025 reached $954.3 million, up 31.15%, while the annual FY2025 figure was $954.3 million, 31.15% up from the prior year.
  • Common Equity reached $954.3 million in Q4 2025 per CPRX's latest filing, up from $920.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $954.3 million in Q4 2025 to a low of $178.7 million in Q1 2021.
  • Average Common Equity over 5 years is $466.7 million, with a median of $361.9 million recorded in 2023.
  • Peak YoY movement for Common Equity: grew 21.95% in 2021, then soared 89.63% in 2024.
  • A 5-year view of Common Equity shows it stood at $206.8 million in 2021, then surged by 45.25% to $300.4 million in 2022, then grew by 29.11% to $387.9 million in 2023, then soared by 87.59% to $727.6 million in 2024, then surged by 31.15% to $954.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Common Equity are $954.3 million (Q4 2025), $920.2 million (Q3 2025), and $856.0 million (Q2 2025).